Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity

Kinase inhibitors (KIs) used in cancer therapeutics are associated with various side effects. One of the most significant adverse events that lead to discontinuation or modification of treatment is nephrotoxicity. We have identified BCR-ABL1 inhibitor dasatinib as a potential glomerular nephrotoxin due to its direct effect on podocyte biophysics. In order to understand the underlying molecular mechanisms used phospho-tyrosine enriched shotgun proteomics in immortalized mouse kidney podocytes treated with dasatinib.